Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774907 | 0.97 | — | — | |
| SCHEMBL128409 | 0.92 | — | — | |
| SCHEMBL131068 | 0.85 | — | — | |
| SCHEMBL9357814 | 0.82 | — | — | |
| SCHEMBL595778 | 0.82 | CYP2C19 (0.37) | CYP2C19USP2TSHRALDH1A1 | |
| SCHEMBL596112 | 0.77 | CYP2C19 (0.34) | CYP2C19USP2TSHRALDH1A1 | |
| SCHEMBL1039602 | 0.77 | — | — | |
| SCHEMBL596917 | 0.77 | CYP2C19 (0.34) | CYP2C19USP2TSHRALDH1A1 | |
| SCHEMBL5505112 | 0.76 | CYP2C19 (0.32) | CYP2C19USP2TSHRALDH1A1 | |
| SCHEMBL1580146 | 0.74 | CYP2C19 (0.33) | CYP2C19USP2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. | 2003-11-06 | — | — | US | claimed |
| EP-1292574-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-02-28 | — | — | US | claimed |
| WO-2001098267-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | claimed |
| WO-2014167133-A1 | FUNGICIDES COMPRISING BORON | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | WO | disclosed |
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1292574-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-02-28 | — | — | US | disclosed |
| WO-2001098267-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES HAVING OPIOID RECEPTOR AFFINITY | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | CYP2C19 175/4885USP2 2749/4885TSHR 2306/4885 |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | CYP2C19 175/4885USP2 2749/4885TSHR 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.